Mustafa Akkaya1,2, Antonio Pignataro3, Nemandra Sandiford4, Thorsten Gehrke1, Mustafa Citak5. 1. Department of Orthopaedic Surgery, Helios ENDO-Klinik, Hamburg, Germany. 2. Department of Orthopaedics and Traumatology, Ankara Yıldırım Beyazıt University, Ankara, Turkey. 3. Medical School of Università Degli Studi Gabriele D'Annunzio, Pescara, Italy. 4. Joint Reconstruction Unit, Southland Hospital, Invercargill, New Zealand. 5. Department of Orthopaedic Surgery, Helios ENDO-Klinik, Hamburg, Germany. mcitak@gmx.de.
Abstract
PURPOSE: Acromegaly is a rare and chronic hormonal disorder. Persons with acromegaly frequently live well into adulthood. Patients with active acromegaly have multiple joint-related issues; however, acromegalic arthropathy (AA), which is secondary osteoarthritis (OA), is considered one of the most common musculoskeletal complications of acromegaly. This study aims to analyze a cohort of patients who underwent total hip arthroplasty (THA) for AA at our institution and present the long-term clinical outcomes and causes of revision in these patients. METHODS: All patients, who underwent total hip arthroplasty due to secondary osteoarthritis related to acromegaly between January 2001 and December 2019 at our institution, were included in this retrospective study. There were 15 patients (22 hips) with a mean follow-up of 12 years (range 4-20). Survivorship free of component revision was determined using Kaplan-Meier analysis. Patient-reported clinical outcomes were assessed using Harris Hip Scores. RESULTS: At the final follow-up, the status of the implant was known in all 15 hips. No patients were lost to follow-up. Five patients (9 hips) were deceased. Three hips (14%) underwent a revision surgery at a mean of six years (range 3-10). Survivorship free of component revision was 81% at 15 years. Mean Harris Hip Scores at final follow-up were fair (mean 64.3, range 32-91), but significantly improved compared to preoperative scores (p < 0.05). CONCLUSION: Acromegaly is a rare disorder that has direct effects on bone and joints. Our results suggest that THA can result in successful clinical and functional outcomes in patients with AA of the hip however the risk of aseptic loosening should also be considered in this patient population.
PURPOSE: Acromegaly is a rare and chronic hormonal disorder. Persons with acromegaly frequently live well into adulthood. Patients with active acromegaly have multiple joint-related issues; however, acromegalic arthropathy (AA), which is secondary osteoarthritis (OA), is considered one of the most common musculoskeletal complications of acromegaly. This study aims to analyze a cohort of patients who underwent total hip arthroplasty (THA) for AA at our institution and present the long-term clinical outcomes and causes of revision in these patients. METHODS: All patients, who underwent total hip arthroplasty due to secondary osteoarthritis related to acromegaly between January 2001 and December 2019 at our institution, were included in this retrospective study. There were 15 patients (22 hips) with a mean follow-up of 12 years (range 4-20). Survivorship free of component revision was determined using Kaplan-Meier analysis. Patient-reported clinical outcomes were assessed using Harris Hip Scores. RESULTS: At the final follow-up, the status of the implant was known in all 15 hips. No patients were lost to follow-up. Five patients (9 hips) were deceased. Three hips (14%) underwent a revision surgery at a mean of six years (range 3-10). Survivorship free of component revision was 81% at 15 years. Mean Harris Hip Scores at final follow-up were fair (mean 64.3, range 32-91), but significantly improved compared to preoperative scores (p < 0.05). CONCLUSION: Acromegaly is a rare disorder that has direct effects on bone and joints. Our results suggest that THA can result in successful clinical and functional outcomes in patients with AA of the hip however the risk of aseptic loosening should also be considered in this patient population.
Authors: M J E Wassenaar; N R Biermasz; M Kloppenburg; A A van der Klaauw; J Tiemensma; J W A Smit; A M Pereira; F Roelfsema; H M Kroon; J A Romijn Journal: Growth Horm IGF Res Date: 2010-03-02 Impact factor: 2.372
Authors: Laurence Katznelson; Edward R Laws; Shlomo Melmed; Mark E Molitch; Mohammad Hassan Murad; Andrea Utz; John A H Wass Journal: J Clin Endocrinol Metab Date: 2014-10-30 Impact factor: 5.958
Authors: Nienke R Biermasz; Alberto M Pereira; Jan W A Smit; Johannes A Romijn; Ferdinand Roelfsema Journal: J Clin Endocrinol Metab Date: 2005-03-01 Impact factor: 5.958
Authors: M J E Wassenaar; N R Biermasz; N van Duinen; A A van der Klaauw; A M Pereira; F Roelfsema; J W A Smit; H M Kroon; M Kloppenburg; J A Romijn Journal: Eur J Endocrinol Date: 2008-12-02 Impact factor: 6.664
Authors: Nienke R Biermasz; Friedo W Dekker; Alberto M Pereira; Sjoerd W van Thiel; Pieter J Schutte; Hans van Dulken; Johannes A Romijn; Ferdinand Roelfsema Journal: J Clin Endocrinol Metab Date: 2004-06 Impact factor: 5.958
Authors: B Swearingen; F G Barker; L Katznelson; B M Biller; S Grinspoon; A Klibanski; N Moayeri; P M Black; N T Zervas Journal: J Clin Endocrinol Metab Date: 1998-10 Impact factor: 5.958
Authors: Jakob Dal; Ulla Feldt-Rasmussen; Marianne Andersen; Lars Ø Kristensen; Peter Laurberg; Lars Pedersen; Olaf M Dekkers; Henrik Toft Sørensen; Jens Otto L Jørgensen Journal: Eur J Endocrinol Date: 2016-06-08 Impact factor: 6.664